Tag Archives: Merck KgAA

Germany’s Merck puts consumer drugs business up for sale; does this signal a last-ditch shot at M&A or just shoring up existing pipeline?

The News: Merck KGaA (Darmstadt DEU) put its consumer-health unit on the block Tuesday (September 5, 2017) in a move that will focus its healthcare activities on the riskier business… Read more »

Breakthrough gene editing reported that removes deadly embryonic mutations; biotech licks its chops as stakes are incalculable for ensuing blockbusters.

The News: Scientists have modified human embryos to remove genetic mutations that cause heart failure in otherwise healthy young people in a landmark demonstration of the controversial procedure, The Guardian… Read more »

Update: Merck KGaA, Pfizer score landmark FDA nod for checkpoint contender Avelumab

This is an update to my story: “German Merck, flying under Street’s radar, gets no respect; but not for long” Germany’s Merck KGaA and part­ner Pfizer Inc. came away with… Read more »

German Merck, flying under Street’s radar, gets no respect; but not for long

Steve’s Take: Wall Street analysts are perhaps familiar with the history behind the two Pharma powerhouses, US-based Merck & Co., and Germany-based Merck KgaA. Until recently, however, I only had… Read more »

FTC opens antitrust investigation of Mylan’s EpiPen dominance; isn’t it high time we live up to Churchill’s rejoinder?

The News: Mylan on Monday (January 30, 2017) acknowledged that the US Federal Trade Commission asked the company “months ago” to provide information about the allergy therapy EpiPen (epinephrine) as… Read more »

Mylan Plans Generic EpiPen to Calm Pricing Outrage; Feels More Like a PR Move

Mylan NV’s latest attempt to deflect criticism over the price of allergy shot EpiPen failed to get the drugmaker out of the crosshairs of Congress this week. Last week, Chief… Read more »